Skip to main content

Research Repository

Advanced Search

All Outputs (8)

Design of a new class of broad-spectrum therapeutics targeted to drug-resistant bacteria (2024)
Journal Article
Surendran, A., Turnbull, A., Flockhart, A., Findlay-Greene, F., Nowosielska, M., Morrison, D., Mincher, D. J., & Donnellan, S. (2024). Design of a new class of broad-spectrum therapeutics targeted to drug-resistant bacteria. All Life, 17(1), Article 2379309. https://doi.org/10.1080/26895293.2024.2379309

We hypothesise that antimicrobial resistance (AMR) cannot be overcome by simply ‘drugging’ single biological targets, therefore, our focus is developing broad-spectrum therapeutics. Herein we present the synthesis of two novel spacer-linked, anthraqu... Read More about Design of a new class of broad-spectrum therapeutics targeted to drug-resistant bacteria.

Design of new anticancer drugs by selectable intracellular organelle targeting: make for the mitochondria or turn left for the lysosome? (2024)
Presentation / Conference Contribution
Mincher, D., Kamel, M., Mohammed, O., MacCallum, J., & Turnbull, A. (2024, June). Design of new anticancer drugs by selectable intracellular organelle targeting: make for the mitochondria or turn left for the lysosome?. Presented at EACR 2024: Innovative Cancer Science, Rotterdam, Netherlands

Introduction
Defining structural features that can control and pinpoint the delivery of drugs to specific sub-cellular organelles ofcancer cells offers the prospect of designing more potentand selective drugs that negate drug resistance, with less d... Read More about Design of new anticancer drugs by selectable intracellular organelle targeting: make for the mitochondria or turn left for the lysosome?.

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo (2019)
Journal Article
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (2020). Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, 26, 1965-1980. https://doi.org/10.1007/s10989-019-09994-1

The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Overexpression, coupled with highly selective specificity for cleavage of sub... Read More about Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo.

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections (2016)
Presentation / Conference Contribution
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September). Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece

Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Reduced bioavailability and sub-optimal doses can be responsible for generatio... Read More about Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections.

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer (2016)
Presentation / Conference Contribution
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biomarker and a molecular target for imaging and drug targeting. Legumain is a... Read More about Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer.

Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. (2005)
Journal Article
Dias, N., Goossens, J.-F., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., Bernal, J., Turnbull, A., Mincher, D., & Bailly, C. (2005). Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry, 16(4), 949-958. https://doi.org/10.1021/bc050065x

We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derived from 1,8-dihydroxyanthracene-9,10-dione, were studied for DNA binding and... Read More about Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents..